This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nakamae H, Storer B, Sandmaier BM, Maloney DG, Davis C, Corey L et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: Impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011; 96: 1838–1845.
Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004; 33: 419–423.
First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM . Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndrome. Blood 1985; 65: 368–374.
Nash RA, Gooley T, Davis C, Appelbaum FR . The problem of thrombocytopenia after hematopoietic stem cell transplantation. Stem Cells 1996; 14 (Suppl 1): 261–273.
Dominietto A, Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Berisso G et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219–227.
Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 154–162.
Seber A, Shu XO, Defor T, Sencer S, Ramsay N . Risk factors for severe hemorrhagic cystitis following Bone marow transplantation. Bone Marrow Transplant 1999; 23: 35–40.
Trotman J, Nivison-Smith I, Dodds A . Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration. Bone Marrow Transplant 1999; 23: 797–801.
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol. Blood Marrow Transplant 2014; 20: 382–386.
Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404–409.
Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116: 3163–3170.
Acknowledgements
This work was supported by educational grants from the ‘Association for Training, Education and Research in Hematology, Immunology and Transplantation’ (ATERHIT). We also thank the ‘Association pour la Recherche sur le Cancer (ARC)’, the ‘Fondation de France’, the ‘Fondation contre la Leucémie’, the ‘Agence de Biomédecine’, the ‘Association Cent pour Sang la Vie’, the ‘Association Laurette Fugain’, the ‘IRGHET’ and the ‘Ligue Contre le Cancer’ (Comités Grand-Ouest), for their generous and continuous support to our clinical and basic research work. Our transplant programs are supported by several grants from the French National Cancer Institute. We are grateful to Professor Junia V Melo (University of Adelaide, Australia, and Imperial College, London) for medical editing of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interests.
Rights and permissions
About this article
Cite this article
Battipaglia, G., Ruggeri, A., Brissot, E. et al. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant 50, 1574–1577 (2015). https://doi.org/10.1038/bmt.2015.182
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.182
This article is cited by
-
Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
Bone Marrow Transplantation (2021)
-
Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies
Bone Marrow Transplantation (2020)